Healthcare Industry News: Roche Group
News Release - May 14, 2007
Dan Zabrowski Appointed Global Head, Roche Pharma Partnering
NUTLEY, N.J., May 14 (HSMN NewsFeed) -- Roche has announced that Dan Zabrowski, Ph.D., currently Global Head Pharma Development Operations in Nutley, NJ, will assume the position of Global Head, Roche Pharma Partnering effective July 1, 2007. In his new assignment, Zabrowski will oversee Roche's world-class network of strategic alliances with biotech companies and create new alliances in the future. He will report to William M. Burns, CEO, Pharmaceuticals Division, Roche. Zabrowski succeeds Peter Hug, who will become Head of the Roche Pharmaceuticals Western Europe Region.According to William M. Burns, "Roche's focus on building strong and lasting partnerships has become an industry standard, and Dan's strong background in drug development and regulatory affairs will be particularly important as we continue to expand our network of more than 60 global partners."
"Innovation is the foundation for everything that we do at Roche. I look forward to working with all of our partner companies as well as creating new exciting relationships to advance the development of new, effective treatments that can help patients worldwide," said Zabrowski.
Currently, Zabrowski is responsible for both the U.S. Development organization in Nutley and the management of all global clinical trials for the Pharma Division. Prior to this, he served as head, Global Regulatory Affairs at Roche. He joined Roche in 1995 following the company's acquisition of Syntex, Inc., where he held a variety of positions in Regulatory Affairs. Before Syntex, Zabrowski led Regulatory Affairs in North America for Fujisawa Pharmaceutical Company. He began his career as a researcher at G.D. Searle Pharmaceuticals.
About Roche
Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or www.roche.us.
Source: Roche Group
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Roche Receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App Integration, Offering an Enhanced Diabetes Management ExperienceRoche Receives CE IVDR Approval for HER2 (4B5) Companion Diagnostic Test to Identify HER2-ultralow Breast Cancer and Biliary Tract Cancer Patients
